RenovoRx Reports Milestone Q3 Revenue Exceeding $1 Million and Maintains 2026 Guidance
RenovoRx (RNXT) achieved a significant financial milestone in the third quarter of 2026, reporting quarterly revenue that exceeded $1 million for the first time in the company's history. CEO Shaun Bagai characterized the period as a milestone quarter for the organization. Looking ahead, the company has maintained its full-year 2026 revenue guidance, projecting earnings between $3.75 million and $4.25 million. As part of its growth strategy, RenovoRx is actively targeting expansion into 36 active cancer centers to drive future commercial scaling.
